All articles tagged with #gpr133
Researchers link the GPR133 (ADGRD1) receptor to bone density, showing that activating it with the chemical AP503 strengthens bones in mice and works with exercise, suggesting a potential path to reversing osteoporosis—though human trials are still needed and findings are currently in animal models.
Researchers have identified GPR133 (ADGRD1) as a master switch in bone-building cells; when activated by the compound AP503, it boosts osteoblast activity and suppresses bone-destroying cells in mice, reversing early bone loss and hinting at a future osteoporosis drug. At the same time, a Penn State prune trial found that postmenopausal women who eat 50–100 g of prunes daily maintain cortical bone density and estimated strength over 12 months, using 3D bone measurements. Together, the studies underscore prevention over reversal—bone loss begins well before fractures, with perimenopause a critical window—and while the drug findings are preclinical, the prune results offer an immediately actionable dietary approach, plus ongoing trials into perimenopause. Human trials are still needed, but these lines point to new bone-health strategies.
Scientists identified GPR133 as a receptor that senses mechanical strain and coordinates osteoblasts and osteoclasts, acting as a switch to boost bone formation while reducing bone degradation. In mice, activating GPR133 with the compound AP503 increased bone strength in both healthy and osteoporosis models, suggesting a balanced, potentially safer new approach to osteoporosis treatment, though human trials are needed.
Leipzig University researchers have identified GPR133 (ADGRD1) as a mechanosensitive receptor that promotes bone formation and limits bone resorption, strengthening bones. The receptor can be activated by AP503, which improved bone strength in both healthy and osteoporosis-model mice, offering a potential new drug target for osteoporosis and possibly age-related bone and muscle decline. Findings are preclinical, and further studies are needed before human treatments.
New research shows that activating the GPR133 receptor with the compound AP503 boosts osteoblast-driven bone formation, dramatically increasing bone density and strength in osteoporotic mice and even stronger when combined with exercise; the approach could shift osteoporosis treatment from slowing bone loss to rebuilding bone, but it remains early-stage animal research with no human trials yet.
A 2025 study from Leipzig and Shandong identifies the GPR133 (ADGRD1) receptor as crucial for bone density. Activating it with the chemical AP503 increases osteoblast activity and bone strength in mice, suggesting a potential therapy for osteoporosis that could work with exercise. While promising, these results are in animal models and require human testing; related 2024 work on a blood‑based regenerative implant and bone‑density hormones may inform future treatments.
A recent study identifies the GPR133 receptor as a key to strengthening bones and potentially reversing osteoporosis, with experiments showing that activating this receptor in mice improves bone density and strength. The research also explores innovative blood-based implants for bone repair and highlights promising hormonal and molecular targets for future treatments, though most findings are still in animal models.
Scientists at Leipzig University discovered that activating the GPR133 receptor can strengthen bones and potentially treat osteoporosis, with the substance AP503 showing promise in increasing bone strength in mice, highlighting a new target for therapies to combat age-related bone loss.
Scientists in Germany discovered a receptor called GPR133 that can be activated by a compound named AP503 to boost bone density and potentially treat osteoporosis, showing promise for improving bone strength in aging populations.